Iovance Biotherapeutics Hits Day High with Strong 7.3% Intraday Surge

Iovance Biotherapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 7.3% on July 17, 2026. The stock reached an intraday high of USD 5.07, showcasing its notable activity in the market. Over the past week, Iovance has surged by 18.2%, and its one-month performance stands at an impressive 27.23%. In the last year, the stock has generated a remarkable return of 113.68%, significantly outperforming the S&P 500, which recorded an 18.43% return during the same period. Despite this strong performance, the company has faced challenges, with profits declining by 3.7% over the past year. Iovance Biotherapeutics operates within the Pharmaceuticals & Biotechnology industry and holds a market capitalization of USD 1,446 million. The company has maintained positive results for the last eight consecutive quarters, although it remains in a loss-making position with a return on equity of -55.23%. Institutional holdings are notably high at 79.05%, indicating a strong interest from larger investors who typically have more resources to analyze company fundamentals.